Rein Therapeutics Inc. RNTX
0.34 USD -0.03 (-8.38%)
Regular-session close
0.39 +0.05 +15.76%
After hours · Nov 20, 6:46 PM ET
0.3352 Day range 0.3899
0.284 52-week range 2.10
- YTD
- -70.96%
- 1 year
- -75.59%
News
benzinga.com HC Wainwright & Co. Reiterates Buy on Rein Therapeutics, Maintains $8 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Rein Therapeutics (NASDAQ:RNTX) with a Buy and maintains $8 price target.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Akanda (NASDAQ:AKAN) stock rose 42.6% to $1.94 during Monday's regular session. The market value of their outstanding shares is at $3.5 million. CEL-SCI (AMEX:CVM) shares increased by 30.46%…benzinga.com Rein Therapeutics Reports Preliminary 12-Week Blinded Phase 2 RENEW Data For LTI-03 In IPF Patients; Study Achieves 75% Enrollment, With 90 Patients Randomized To Date; On Track To Report Topline Data In 2027 33% of evaluable patients demonstrated improvement over baseline in forced vital capacity (FVC) at Week 12From baseline, change in FVC ranged from an improvement of 338 ml to a decline of 349 ml at…
globenewswire.com Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial Results AUSTIN, Texas, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and…benzinga.com Rein Therapeutics Q3 EPS $(0.06) Beats $(0.10) Estimate Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.10) by 40 percent. This is a 71.43 percent increase over losses of…
